interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Deucravacitinib

Generic competition · all medicines · read 12 November 2026

Is there a generic of Deucravacitinib, and who makes it?

Deucravacitinib appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Deucravacitinib1 dosage-form group in the Orange Book
0generic makers listed
  1. Deucravacitinib appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Sotyktu. No generic is listed as marketed.

20202025203020352040204501brand 2022data datePatent RE47929 listed to expire 7 November 2033Patent 11021475 listed to expire 7 November 2033Patent 10000480 listed to expire 7 November 2033Patent 12734169 listed to expire 18 September 2040Patent 12521390 listed to expire 11 February 2043Exclusivity NCE to 9 September 2027Exclusivity I-986 to 6 March 2029
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 9 September 2027Exclusivity NCE Sotyktu
  • 6 March 2029Exclusivity I-986 Sotyktu
  • 7 November 2033Patent RE47929 drug substance
  • 7 November 2033Patent 11021475
  • 7 November 2033Patent 10000480 drug substance
  • 18 September 2040Patent 12734169 drug product
  • 11 February 2043Patent 12521390 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.